Forte Biosciences
Forte Biosciences (Nasdaq: FBRX) is being acquired by argenx SE in an all-cash deal valued at about $2.2 billion, or $77.00 per share, announced July 27, 2026, with expected Q3 2026 closing. The offer follows FB102 Phase Ib results in vitiligo and celiac disease, and includes FDA Fast Track for celiac. Forte raised $172.5M in April 2026.
How this was made
The 30-second read
Why it matters
The definitive all-cash acquisition at a stated per-share price shifts FBRX from fundamental trial-risk trading to deal-risk trading, where the primary variables become regulatory clearance and deal closing mechanics.
Market read
Definitive M&A terms (price, cash funding, expected close quarter) are actionable for traders managing merger spreads and event-driven risk in the target.
What to watch
The article notes no financing condition, but does not quantify regulatory timelines or potential remedies, which are key drivers of merger-spread volatility.
Background
Forte is a clinical-stage biotech built around FB102, an anti-CD122 monoclonal antibody, with Phase Ib data in celiac disease and vitiligo and earlier-stage work in alopecia areata.
Ticker impact
Forte Biosciences agreed to be acquired by argenx for $77.00 per share in an all-cash deal expected to close in Q3 2026.
Near-term upside is likely capped by the $77.00 offer, with volatility driven by antitrust clearance headlines and any deal-conditions updates.
The article discloses a definitive merger agreement, offer price, funding source, and expected closing quarter, which directly governs valuation and spread dynamics for the target.
Market effects
Reinforces immunology-focused CD122 pathway M&A interest and may raise perceived strategic value of similar autoimmune antibody programs.
Limited direct regional spillover beyond US small/mid-cap biotech deal flow.
Cross-border acquirer (argenx) highlights continued European biotech appetite for late-stage autoimmune assets.
Counterpoint
Offer-spread trades can unwind quickly if antitrust clearance or other customary conditions face delays, making downside possible even with a premium.
Key entities
- companyForte Biosciences
Nasdaq-listed clinical-stage biotech developing FB102 (anti-CD122) for autoimmune indications.
- acquirerargenx SE
Agreed to acquire Forte in an all-cash transaction valued at about $2.2 billion, expected to close in Q3 2026.
- assetFB102
Forte’s anti-CD122 monoclonal antibody in celiac disease, non-segmental vitiligo, and alopecia areata.
